EyePoint Pharmaceuticals (EYPT) CEO On Ophthalmic Products & Earnings

EyePoint Pharmaceuticals (EYPT) is focused on developing and commercializing ophthalmic products. CEO, Nancy Lurker discusses EYPT as its pipeline leverages its durasert technology for sustained intraocular drug delivery. She talks about EYPT's latest clinical trials, as well as its most recent earnings which were released on May 3rd. Its adjusted EPS came in at -$0.56 versus an estimated -$0.65 and its revenue came in at $7.68M versus an estimated $7.43M. She then goes over some upcoming catalysts for EYPT. Tune in to find out more about the stock market today.